Prostaglandin D synthase in the prenatal ovine brain and effects of its inhibition with selenium chloride on fetal sleep/wake activity in utero.
It has been proposed that prostaglandin (PG) D(2) induces physiological sleep in mammals by acting on sleep centers located in the anterior hypothalamus. In fetal sheep, definitive rapid-eye-movement and non-rapid-eye-movement sleep states appear at approximately 125 d gestation (term is approximately 147 d). In adult animals, PGD synthase (PGDS) (functionally and structurally homologous to beta-trace protein) is secreted into CSF with a circadian pattern, with the highest concentrations present during sleep. In this study we show that PGDS/beta-trace protein is present in fetal sheep CSF at 125 and 135 d gestation but not at 90 d gestation. SeCl(4), a specific inhibitor of PGDS, was given to unanesthetized fetal sheep (130-140 d gestation) by intracerebroventricular infusion at a dose of 25, 100, 500, or 1000 pmol/min for 4 hr. Artificial CSF was infused in control experiments. Arousal behavior, defined as the presence of nuchal muscle electromyogram activity, electro-ocular activity, and breathing movements during low-amplitude electrocortical activity, increased from 3.8 +/- 1 min/hr to 6.6 +/- 0.5 and 7.0 +/- 0.3 min/hr at doses of 100 and 500 pmol/min, respectively (p < 0.05). SeCl(4) at 25 and 1000 pmol/min had no significant effect on arousal activity. Infusion of PGD(2) at 500 pmol/min intracerebroventricularly for 4 hr decreased the incidence of arousal from 3.8 +/- 0.5 min/hr to 0.7 +/- 0.3 min/hr (p < 0.05). When 500 pmol/min PGD(2) was infused immediately after a 4 hr infusion of SeCl(4) (500 pmol/min), the SeCl(4)-induced increase in arousal behavior was abolished. Together, the presence of PGDS/beta-trace protein in fetal CSF in late gestation and the effects of SeCl(4) in increasing the incidence of arousal-like behavior suggest that PGD(2) has a role in the induction and maintenance of prenatal sleep.
Lee
Brenda
B
Department of Physiology, Monash University, Clayton, Melbourne, Victoria, Australia, 3800.
Hirst
Jonathan J
JJ
Walker
David W
DW
D000818:Animals; D001143:Arousal; D001921:Brain / Q000196:embryology* / Q000201:enzymology* / Q000502:physiology; D002552:Cerebral Ventricles; D002712:Chlorides / Q000008:administration & dosage / Q000494:pharmacology*; D005314:Embryonic and Fetal Development; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005333:Fetus / Q000201:enzymology / Q000502:physiology; D006801:Humans; D007263:Infusions, Parenteral; D019746:Intramolecular Oxidoreductases / Q000037:antagonists & inhibitors* / Q000134:cerebrospinal fluid; D007700:Kinetics; D054834:Lipocalins; D011247:Pregnancy; D015230:Prostaglandin D2 / Q000008:administration & dosage / Q000494:pharmacology; D018036:Selenium Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D012756:Sheep; D012890:Sleep / Q000187:drug effects; D014851:Wakefulness / Q000187:drug effects
D002712:Chlorides; D004791:Enzyme Inhibitors; D054834:Lipocalins; D018036:Selenium Compounds; C070974:selenium tetrachloride; D019746:Intramolecular Oxidoreductases; C022466:prostaglandin R2 D-isomerase; D015230:Prostaglandin D2